GlassScriptPhysician profile
Keiler Moreno Rivero
NPI 1659780625
$1,867.48
in general payments reported to CMS, 2019-2025
26 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.34 · 2020: $317 · 2021: $342 · 2022: $95.87 · 2023: $233 · 2024: $334 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $299.07 | 2019-2021 | |
| Pfizer INC. | $228.14 | 2020-2025 | |
| Abbvie INC. | $163.57 | 2023-2024 | |
| Lilly USA, LLC | $135.89 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $135.80 | 2023-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $135.35 | 2022-2025 | Freestyle Libre |
| Phathom Pharmaceuticals, INC. | $114.38 | 2025 | Voquezna |
| Novo Nordisk INC | $113.50 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $75.97 | 2023-2025 | |
| Mylan Specialty L.P. | $63.96 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $54.36 | 2021-2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $54.18 | 2021-2023 | Rexulti |
| Protega Pharmaceutials INC | $53.12 | 2025 | Roxybond |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.14 | 2022-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $31.65 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $25.30 | 2024 | Dexcom G6 Transmitter |
| Phadia US INC. | $23.57 | 2024 | Immunocap |
| Abiomed | $20.92 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.20 | 2022 | |
| Philips North America LLC | $18.82 | 2025 | Extended Holter |
| Kowa Pharmaceuticals America, INC. | $16.91 | 2022 | |
| Corcept Therapeutics | $15.32 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $14.25 | 2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $11.11 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keiler Moreno Rivero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.